PTHS Chromocell Therapeutics Corp

NYSE chromocell.com


$ 34.50 $ -1.07 (-3.09 %)    

Friday, 14-Nov-2025 15:47:38 EST
QQQ $ 608.45 $ 0.46 (0.08 %)
DIA $ 471.65 $ -2.94 (-0.62 %)
SPY $ 671.62 $ -0.11 (-0.02 %)
TLT $ 88.93 $ -0.51 (-0.57 %)
GLD $ 375.82 $ -6.91 (-1.8 %)
$ 33.61
$ 33.00
$ 33.77 x 100
$ 35.12 x 100
$ 29.47 - $ 34.50
$ 4.50 - $ 54.29
42,068
na
102.9M
nm
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-13-2025 09-30-2025 10-Q
2 08-13-2025 06-30-2025 10-Q
3 05-13-2025 03-31-2025 10-Q
4 03-27-2025 12-31-2024 10-K
5 11-13-2024 09-30-2024 10-Q
6 08-13-2024 06-30-2024 10-Q
7 05-15-2024 03-31-2024 10-Q
8 04-16-2024 12-31-2023 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

Oppenheimer analyst Jeff Jones reiterates Pelthos Therapeutics (AMEX:PTHS) with a Outperform and raises the price target fro...

Core News & Articles

Pelthos Therapeutics (AMEX:PTHS) reported quarterly losses of $(5.30) per share which missed the analyst consensus estimate of ...

Core News & Articles

Oppenheimer analyst Jeff Jones initiates coverage on Pelthos Therapeutics (AMEX:PTHS) with a Outperform rating and announces...

Core News & Articles

Pelthos Therapeutics (AMEX:PTHS) reported quarterly losses of $(5.38) per share which beat the analyst consensus estimate of $(...

 pelthos-therapeutics-launches-first-at-home-prescription-gel-for-highly-contagious-skin-disease

Pelthos launches Zelsuvmi, the first FDA-approved at-home prescription gel for molluscum, shown to clear lesions in as little a...

Core News & Articles

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced that its partner Pelthos Therapeutics Inc. (NYSE:PTHS) has co...

Core News & Articles

- SEC Filing

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION